Exosomal miRNA Profiling for Detection of Extrahepatic Metastasis in Colorectal Liver Metastases

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Colorectal cancer is the third most common malignancy worldwide, and prognosis largely depends on how effectively metastatic disease is managed. The liver is the most frequent and prognostically important site of metastasis, and patients responding well to chemotherapy may become candidates for curative hepatic resection. However, the presence of extrahepatic metastasis (EHM) critically influences treatment eligibility and survival. Although clinical scores such as the Fong and Beppu systems include EHM as a determinant, its detection by imaging remains limited, especially for small or occult lesions. Accurate identification of EHM is also essential when considering liver transplantation for unresectable colorectal liver metastases (CRLM), where EHM remains an exclusion criterion. The EXMETIS Study aims to develop a non-invasive diagnostic model using serum exosomal microRNAs (miRNAs) to detect both hepatic and extrahepatic metastases in patients with CRLM. By integrating circulating miRNA profiling with machine learning-based analysis, this study seeks to supplement imaging diagnostics, improve treatment stratification, and enhance clinical decision-making for metastatic colorectal cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults (≥18 years old)

• Histologically- or cytologically-confirmed colorectal cancer that is metastatic

• Availability of pre-treatment plasma samples

• Written informed consent provided

• Sufficient clinical and imaging data to determine presence/absence of extrahepatic metastasis

Locations
United States
California
City of Hope Medical Center
RECRUITING
Duarte
Contact Information
Primary
Ajay Goel, PhD
AJGOEL@COH.ORG
626-218-3452
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2026-06-18
Participants
Target number of participants: 500
Treatments
Extrahepatic liver metastasis patients(Discovery Cohort)
Patients with colorectal liver metastases (CRLM) who have confirmed extrahepatic metastasis at the time of diagnosis or treatment planning, included in the first (discovery) cohort.
Non-extrahepatic liver metastasis patients(Discovery Cohort)
Group/Cohort Description: Patients with colorectal liver metastases (CRLM) who do not have confirmed extrahepatic metastasis at the time of diagnosis or treatment planning, included in the first (discovery) cohort.
Extrahepatic liver metastasis patients(Training Cohort)
Extrahepatic liver metastasis patients (Training Cohort) Group/Cohort Description: Patients with colorectal liver metastases (CRLM) who have confirmed extrahepatic metastasis at the time of diagnosis or treatment planning, included in the first (training) cohort.
Non-extrahepatic liver metastasis patients (Training Cohort)
Group/Cohort Description: Patients with colorectal liver metastases (CRLM) who do not have confirmed extrahepatic metastasis at the time of diagnosis or treatment planning, included in the (training) cohort.
Extrahepatic liver metastasis patients (Validation Cohort)
Group/Cohort Description: Patients with colorectal liver metastases (CRLM) who have confirmed extrahepatic metastasis at the time of diagnosis or treatment planning, included in the second, independent, validation cohort
Non-extrahepatic liver metastasis patients (Validation Cohort)
Group/Cohort Description: Patients with colorectal liver metastases (CRLM) who do not have confirmed extrahepatic metastasis at the time of diagnosis or treatment planning, included in the second, independent, validation cohort
Sponsors
Leads: City of Hope Medical Center

This content was sourced from clinicaltrials.gov